Recent advances of nanomedicines for liver cancer therapy

Chi, Xiaoqin; Liu, Kun; Luo, Xiangjie; Yin, Zhenyu; Lin, Hongyu; Gao, Jinhao

doi:10.1039/c9tb02871d

Cited by 42 publications

(17 citation statements)

References 276 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of various tumor molecule-targeted treatments was made easy by advancements in medical research and technology in past years, with medicines that target particular molecules showing high success in treating HCC (Xia et al., 2021 ). Molecular therapies are more tumor-specific than standard chemotherapy drugs and more successful in targeting cancer cells (Hlady et al., 2019 ; Chi et al., 2020 ; Lu et al., 2020 ).…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer

Zhang

Han

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is widespread cancer with a high degree of morbidity and mortality in individuals worldwide and a serious concern for its resistance to present chemotherapy drugs. In this investigation, the combination of cisplatin (CPT) and metformin (MET) to kill the HepG2 and caco-2 cells was developed into a new pH-responding magnetic nanocomposite based on reduced graphene oxide. Polyhydroxyethyl methacrylic (PHEA) was then linked employing grafting from approach to the reduced graphene oxide by ATRP polymerization (Fe 3 O 4 @rGO-G-PSEA). FT-IR, SEM, XRD, DLS, and TGA analyses evaluated physicochemical characteristics of the nanocomposite. In addition, the cellular uptake property of the nanocomposites was examined by the HepG2 cells. The outcomes of cell viability results indicate that the nanoparticles loaded with MET&CPT showed the lowest concentration rate of HepG2 and Caco-2 cells compared to the drug-loaded single nanocomposite groups and free drugs. The histological analysis has demonstrated relatively safe and does not produce different stress such as swelling and inflammation of the mice organs. Our results show the enhancement in cytotoxicity in HepG2 and Cocoa-2 cells by MET and CPT graphene oxide-based nanocomposite by promoting apoptotic response. Moreover, Fe 3 O 4 @rGO-G-PSEA showed potent in vivo antitumor efficacy but showed no adverse toxicity to normal tissues. Together, this study can provide insight into how surface embellishment may tune these nanocomposites' tumor specificity and provide the basis for developing anticancer efficacy.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer

Zhang

Han

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Systems for Cancer Treatment Improved chemotherapy requires the drugs to cross the biological barriers followed by their selective localization in the target tumor tissues, thus leading to enhanced anticancer activity with minimum off-target side effects. Passive and active NP drug targeting is a widely used approach [86,87].…”

Section: Recent Advances In Nanocarrier Deliverymentioning

confidence: 99%

“…Such nanocarriers avoid clearance from the body and remain in biological systems for a longer time; thus, they pass through the tumor microenvironment repeatedly with ultimate increased anticancer activity of their loaded drugs. Similarly, cationic nanocarriers are also used to localize their loaded drugs in tumors due to their electrostatic interactions with angiogenic endothelial cells in tumor blood vessels [86,87].…”

Section: Recent Advances In Nanocarrier Deliverymentioning

confidence: 99%

“…Cancer cells overexpress certain types of receptors; thus, targeting moieties recognize these receptors and highly selective drug localization in tumors is achieved [96,97]. Similarly, nanocarriers are also made responsive to the changes in the tumor microenvironment; drugs get released from nanocarriers in the tumor vicinity as a result of their responsiveness to those stimuli such as pH, hyperthermia, redox potential, and certain enzymes in the tumor microenvironment [86,87]. Thus, increased drug concentration is achieved in the tumor microenvironment with ultimate improved chemotherapy.…”

Section: Recent Advances In Nanocarrier Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Recent Trends in Nanocarrier-Based Targeted Chemotherapy: Selective Delivery of Anticancer Drugs for Effective Lung, Colon, Cervical, and Breast Cancer Treatment

Jin

Chen³

et al. 2020

Journal of Nanomaterials

View full text Add to dashboard Cite

Chemotherapy drugs are cytotoxic to tumor cells, but their lack of specificity leads to a range of side effects. The off-target effects of such drugs can be improved through the use of nanoparticles (NPs). Administered NPs show enhanced accumulation in tumor tissue near the blood vessels, enhancing both anticancer drug permeability and tumor retention. Several nanocarriers are now approved for clinical use in a range of cancer therapies, and many novel formulations are in the later stages of clinical trials. Here, we describe the advances in this area through the review of novel NP drug formulations developed over the last year. We focus specifically on lung, colon, cervical, and breast cancers and discuss the future of NPs as potential treatment options in these areas.

show abstract

“…The development of nanotechnology promotes cancer treatment. More than 50 nanodrugs have been introduced for clinical use since 1995 ( Chi et al, 2020 ). Further, several nanodrugs (such as ThermoDox, ALN-VSP, etc.)…”

Section: Introductionmentioning

confidence: 99%

Silica-Based Nanoframeworks Involved Hepatocellular Carcinoma Theranostic

Liu

Chen

Fei

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Silica-based nanoframeworks have been extensively studied for diagnosing and treating hepatocellular carcinoma (HCC). Several reviews have summarized the advantages and disadvantages of these nanoframeworks and their use as drug-delivery carriers. Encouragingly, these nanoframeworks, especially those with metal elements or small molecular drugs doping into the skeleton structure or modifying onto the surface of nanoparticles, could be multifunctional components participating in HCC diagnosis and treatment rather than functioning only as drug-delivery carriers. Therefore, in this work, we described the research progress of silica-based nanoframeworks involved in HCC diagnosis (plasma biomarker detection, magnetic resonance imaging, positron emission tomography, photoacoustic imaging, fluorescent imaging, ultrasonography, etc.) and treatment (chemotherapy, ferroptotic therapy, radiotherapy, phototherapy, sonodynamic therapy, immunotherapy, etc.) to clarify their roles in HCC theranostics. Further, the future expectations and challenges associated with silica-based nanoframeworks were highlighted. We believe that this review will provide a comprehensive understanding for researchers to design novel, functional silica-based nanoframeworks that can effectively overcome HCC.

show abstract

Recent advances of nanomedicines for liver cancer therapy

Abstract: This review highlights recent advancements in nanomedicines for liver cancer therapy.

Cited by 42 publications

References 276 publications

RETRACTED ARTICLE: A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer

RETRACTED ARTICLE: A convergent synthetic platform for dual anticancer drugs functionalized by reduced graphene nanocomposite delivery for hepatocellular cancer

Recent Trends in Nanocarrier-Based Targeted Chemotherapy: Selective Delivery of Anticancer Drugs for Effective Lung, Colon, Cervical, and Breast Cancer Treatment

Silica-Based Nanoframeworks Involved Hepatocellular Carcinoma Theranostic

Contact Info

Product

Resources

About